Herpes zoster in immunocompromised patients: Incidence, timing, and risk factors

American Journal of Medicine

Volumn 118, Issue 12, 2005, Pages 1416.e9-1416.e18

  Wung, Peter K ^a   Holbrook, Janet T ^b   Hoffman, Gary S ^c   Tibbs, Andrea K ^b   Specks, Ulrich ^d   Min, Y I ^b   Merkel, Peter A ^e   Spiera, Robert ^f   Davis, John C ^g   St Clair, E William ^h   McCune, Joseph ⁱ   Ytterberg, Steven R ^d   Allen, Nancy B ^h   Stone, John H ^a,j  

^a JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b JOHNS HOPKINS BLOOMBERG SCHOOL OF PUBLIC HEALTH   (United States)

^c LERNER RESEARCH INSTITUTE   (United States)

^d MAYO CLINIC   (United States)

^e BOSTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^f BETH ISRAEL MEDICAL CENTER   (United States)

^g UNIVERSITY OF CALIFORNIA   (United States)

^h DUKE UNIVERSITY   (United States)

ⁱ UNIVERSITY OF MICHIGAN   (United States)

^j JOHNS HOPKINS UNIVERSITY   (United States)

more..

Author keywords

Herpes zoster; Immunosuppression; Incidence; Renal insufficiency; Wegener's granulomatosis

Indexed keywords

AZATHIOPRINE; CYCLOPHOSPHAMIDE; IMMUNOSUPPRESSIVE AGENT; METHOTREXATE; METHYLPREDNISOLONE; PREDNISONE;

ADULT; AGED; ANAMNESIS; ARTICLE; CLINICAL ARTICLE; COHORT ANALYSIS; CONTROLLED STUDY; CREATININE BLOOD LEVEL; DISEASE COURSE; DISEASE DURATION; FEMALE; FOLLOW UP; HERPES ZOSTER; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; INCIDENCE; INFECTION RATE; INFECTION RISK; KIDNEY FAILURE; MALE; MULTIVARIATE ANALYSIS; PRIORITY JOURNAL; QUESTIONNAIRE; RISK ASSESSMENT; RISK FACTOR; SEX DIFFERENCE; WEGENER GRANULOMATOSIS;

EID: 29244433723     PISSN: 00029343     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.amjmed.2005.06.012     Document Type: Article

References (42)

1. J.W. Gnann Jr, R.J. Whitley Clinical practice. Herpes zoster N Engl J Med. 347 2002 340 346
2. L.M. Schuchter, J.R. Wingard, S. Piantadosi, W.H. Burns, G.W. Santos, R. Saral Herpes zoster infection after autologous bone marrow transplantation Blood. 74 1989 1424 1427
3. S. Gourishankar, J.C. McDermid, G.S. Jhangri, J.K. Preiksaitis Herpes zoster infection following solid organ transplantation incidence, risk factors and outcomes in the current immunosuppressive era Am J Transplant. 4 2004 108 115
4. S.P. Buchbinder, M.H. Katz, N.A. Hessol Herpes zoster and human immunodeficiency virus infection J Infect Dis. 166 1992 1153 1156
5. Y. Kanda, S. Mineishi, T. Saito Long-term low-dose acyclovir against varicella-zoster virus reactivation after allogeneic hematopoietic stem cell transplantation Bone Marrow Transplant. 28 2001 689 692
6. R.S. Chapman, K.W. Cross, D.M. Fleming The incidence of shingles and its implications for vaccination policy Vaccine. 21 2003 2541 2547
7. M.J. Levin, J.G. Smith, R.M. Kaufhold Decline in varicella-zoster virus (VZV)-specific cell-mediated immunity with increasing age and boosting with a high-hose VZV vaccine J Infect Dis. 188 2003 1336 1344
8. M.N. Oxman, M.J. Levin, G.R. Johnson A vaccine to prevent herpes zoster and postherpetic neuralgia in older adults N Engl J Med. 352 2005 2271 2284
9. G.S. Hoffman, G.S. Kerr, R.Y. Leavitt Wegener granulomatosis an analysis of 158 patients Ann Intern Med. 116 1992 488 498
10. E.W. Walton Giant-cell granuloma of the respiratory tract (Wegener's granulomatosis) Br Med J. 34 1958 265 270
11. E. Reinhold-Keller, N. Beuge, U. Latza An interdisciplinary approach to the care of patients with Wegener's granulomatosis long-term outcome in 155 patients Arthritis Rheum. 43 2000 1021 1032
12. WGET Research Group Etanercept in addition to standard therapy in patients with Wegener's granulomatosis N Engl J Med. 352 2005 351 361
13. T.R. Cupps, G.J. Silverman, A.S. Fauci Herpes zoster in patients with treated Wegener's granulomatosis. A possible role for cyclophosphamide Am J Med. 69 1980 881 885
14. L. Guillevin, J.F. Cordier, F. Lhote A prospective, multicenter, randomized trial comparing steroids and pulse cyclophosphamide versus steroids and oral cyclophosphamide in the treatment of generalized Wegener's granulomatosis Arthritis Rheum. 40 1997 2187 2198
15. A.S. Fauci, S.M. Wolff, J.S. Johnson Effect of cyclophosphamide upon the immune response in Wegener's granulomatosis N Engl J Med. 285 1971 1493 1496
16. M.J. Regan, D.B. Hellmann, J.H. Stone Treatment of Wegener's granulomatosis Rheum Dis Clin North Am. 27 2001 863 886, viii
17. C.A. Langford, C. Talar-Williams, K.S. Barron, M.C. Sneller A staged approach to the treatment of Wegener's granulomatosis induction of remission with glucocorticoids and daily cyclophosphamide switching to methotrexate for remission maintenance Arthritis Rheum. 42 1999 2666 2673
18. D. Jayne, N. Rasmussen, K. Andrassy A randomized trial of maintenance therapy for vasculitis associated with antineutrophil cytoplasmic autoantibodies N Engl J Med. 349 2003 36 44
19. C.A. Langford, C. Talar-Williams, M.C. Sneller Use of methotrexate and glucocorticoids in the treatment of Wegener's granulomatosis. Long-term renal outcome in patients with glomerulonephritis Arthritis Rheum. 43 2000 1836 1840
20. J.H. Stone, W. Tun, D.B. Hellman Treatment of non-life threatening Wegener's granulomatosis with methotrexate and daily prednisone as the initial therapy of choice J Rheumatol. 26 1999 1134 1139
21. WGET Research Group Design of the Wegener's granulomatosis etanercept trial (WGET) Control Clin Trials. 23 2002 450 468
22. J.H. Stone Limited versus severe Wegener's granulomatosis baseline data on patients in the Wegener's granulomatosis etanercept trial Arthritis Rheum. 48 2003 2299 2309
23. J.H. Stone, G.S. Hoffman, P.A. Merkel A disease-specific activity index for Wegener's granulomatosis: modification of the Birmingham Vasculitis Activity Score. International Network for the Study of the Systemic Vasculitides (INSSYS) Arthritis Rheum. 44 2001 912 920
24. R.Y. Leavitt, A.S. Fauci, D.A. Bloch The American College of Rheumatology 1990 criteria for the classification of Wegener's granulomatosis Arthritis Rheum. 33 1990 1101 1107
25. National Cancer Institute. Toxicity Grading Scale 1982. Available at: http://ctep.info.nih.gov. Accessed October 7, 2005.
26. R.G. Kost, S.E. Straus Postherpetic neuralgia - pathogenesis, treatment, and prevention N Engl J Med. 335 1996 32 42
27. M.L. McCrary, J. Severson, S.K. Tyring Varicella zoster virus J Am Acad Dermatol. 41 1999 1 14 ; quiz 15-16
28. S.L. Thomas, A.J. Hall What does epidemiology tell us about risk factors for herpes zoster? Lancet Infect Dis 4 2004 26 33
29. M.W. Ragozzino, L.J. Melton 3rd, L.T. Kurland, C.P. Chu, H.O. Perry Population-based study of herpes zoster and its sequelae Medicine (Baltimore). 61 1982 310 316
30. M.R. Zamora Cytomegalovirus and lung transplantation Am J Transplant. 4 2004 1219 1226
31. E.M. Gardner, E. Connick Illness of immune reconstitution recognition and management Curr Infect Dis Rep. 6 2004 483 493
32. J.G. Donahue, P.W. Choo, J.E. Manson, R. Platt The incidence of herpes zoster Arch Intern Med. 155 1995 1605 1609
33. C. Chidiac, J. Bruxelle, J.P. Daures Characteristics of patients with herpes zoster on presentation to practitioners in France Clin Infect Dis. 33 2001 62 69
34. L.E. Kahl Herpes zoster infections in systemic lupus erythematosus risk factors and outcome J Rheumatol. 21 1994 84 86
35. H.M. Moutsopoulos, J.D. Gallagher, J.L. Decker, A.D. Steinberg Herpes zoster in patients with systemic lupus erythematosus Arthritis Rheum. 21 1978 789 802
36. S. Manzi, L.H. Kuller, J. Kutzer Herpes zoster in systemic lupus erythematosus J Rheumatol.f 22 1995 1254 1258
37. M.A. Antonelli, L.W. Moreland, J.E. Brick Herpes zoster in patients with rheumatoid arthritis treated with weekly, low-dose methotrexate Am J Med. 90 1991 295 298
38. E.A. Engels, P.S. Rosenberg, R.J. Biggar Zoster incidence in human immunodeficiency virus-infected hemophiliacs and homosexual men, 1984-1997. District of Columbia Gay Cohort Study. Multicenter Hemophilia Cohort Study J Infect Dis. 180 1999 1784 1789
39. J. Veenstra, A. Krol, R.M. van Praag Herpes zoster, immunological deterioration and disease progression in HIV-1 infection AIDS. 9 1995 1153 1158
40. A. Webster, P. Grint, M.K. Brenner, H.G. Prentice, P.D. Griffiths Titration of IgG antibodies against varicella zoster virus before bone marrow transplantation is not predictive of future zoster J Med Virol. 27 1989 117 119
41. A.M. Arvin, C.M. Koropchak Immunoglobulins M and G to varicella-zoster virus measured by solid-phase radioimmunoassay antibody responses to varicella and herpes zoster infections J Clin Microbiol. 12 1980 367 374
42. A. Abendroth, A.M. Arvin Immune evasion as a pathogenic mechanism of varicella zoster virus Semin Immunol. 13 2001 27 39